We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Cephalon's $125M Antitrust Deal Is Valid, Atty Power Unknown

Law360 (April 20, 2018, 10:34 PM EDT) -- A contract outlining terms of Cephalon Inc.’s $125 million settlement, which resolved allegations it paid competitors to delay generic versions of its Provigil drug, is binding and enforceable, a Pennsylvania federal judge said Friday, but left undetermined if an insurer-claimant’s attorneys were authorized to approve the deal.

In his 37-page ruling, U.S. District Judge Mitchell S. Goldberg stuck to the sole issue put before the court by Cephalon, a unit of Teva Pharmaceuticals USA Inc. — whether or not the terms within the settlement’s memorandum of...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.